Free Trial
NASDAQ:PCVX

Vaxcyte Q2 2025 Earnings Results & Report

Vaxcyte logo
$64.69 -3.93 (-5.73%)
Closing price 04:00 PM Eastern
Extended Trading
$65.83 +1.14 (+1.76%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte missed analyst earnings expectations in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$1.22 versus the -$1.12 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Vaxcyte EPS Results

Actual EPS
-$1.22
Consensus EPS
-$1.12
Beat/Miss
Missed by -$0.10
One Year Ago EPS
-$1.10
EPS Beat Rate
3 of last 8 quarters

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Q2 2025 Earnings FAQ

Vaxcyte (NASDAQ:PCVX) reported earnings of -$1.22 per share for Q2 2025, missing the consensus estimate of -$1.12. The report was announced on Wednesday, August 6, 2025.

Vaxcyte Earnings Headlines

Vaxcyte, Inc. (NASDAQ:PCVX) Stock Has Average Price Target of $110.50
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)
Vaxcyte (PCVX) Expected to Release Earnings on Tuesday
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX) is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response.

The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.

Founded as SutroVax, the company adopted the Vaxcyte name in 2020. It is headquartered in San Carlos, California, and is led by co-founder and Chief Executive Officer Grant Pickering.

View Vaxcyte Profile